Patents by Inventor Catherine Rose SCHOLZ

Catherine Rose SCHOLZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20230089412
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Application
    Filed: May 31, 2022
    Publication date: March 23, 2023
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 11541045
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: January 3, 2023
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • THERAPIES FOR SQUAMOUS CELL CARCINOMAS
    Publication number: 20220071941
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of neoadjuvant therapies or adjuvant therapies to treat squamous cell carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the H-Ras mutant allele frequency.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Inventors: Antonio Gualberto, Catherine Rose Scholz, Vishnu S. Mishra
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 11207314
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 28, 2021
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20210381063
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 9, 2021
    Applicant: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 11124839
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 21, 2021
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 10980793
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: April 20, 2021
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20200000796
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Application
    Filed: August 14, 2019
    Publication date: January 2, 2020
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20200000795
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Application
    Filed: February 21, 2018
    Publication date: January 2, 2020
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 10471055
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: November 12, 2019
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 10426767
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: October 1, 2019
    Assignee: Kura Oncolofy, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 10335404
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: July 2, 2019
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 10292979
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 21, 2019
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20190060303
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Application
    Filed: April 5, 2018
    Publication date: February 28, 2019
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Methods of treating cancer with farnesyltransferase inhibitors
    Patent number: 10137121
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 27, 2018
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20180280376
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 4, 2018
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20180235952
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.
    Type: Application
    Filed: November 21, 2017
    Publication date: August 23, 2018
    Inventors: Antonio GUALBERTO, Catherine Rose Scholz
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 10022364
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: July 17, 2018
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20180193329
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Application
    Filed: February 26, 2018
    Publication date: July 12, 2018
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20180187266
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.
    Type: Application
    Filed: November 2, 2017
    Publication date: July 5, 2018
    Applicant: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz